Physiomics plc (LSE:PYC) has announced that its total income and loss after tax for the year ending June 2025 are set to outperform market expectations, with total income rising by 46% and loss after tax shrinking by 31% compared to the prior year. The company has secured record contract wins, broadened its client portfolio, and entered new therapeutic areas, reflecting strong growth momentum and encouraging revenue prospects ahead.
Despite these positive developments, Physiomics continues to face financial challenges, including declining revenues and ongoing negative profit margins. Technical analysis indicates a bearish trend, and while recent corporate initiatives offer promising avenues for growth, valuation concerns and financial instability remain key hurdles.
About Physiomics
Physiomics plc is a specialist in mathematical modeling, data science, and biostatistics aimed at accelerating drug development and personalized medicine. The company integrates expertise across Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to support biotech and pharmaceutical clients. Its proprietary Virtual Tumour platform has contributed to over 100 commercial projects with partners such as Merck KGaA, Astellas, and Bicycle Therapeutics.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.









